Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Paul Matteis
Stifel Nicolaus Canada Inc., Research Division

Great. Thanks, everybody, for continuing on here. It’s my pleasure to be moderating a chat with Ryan Watts, Founder and CEO of Denali. I’m sure most folks know the story decently well. But maybe, Ryan, you can just give us a couple of minutes to sort of set the stage on 2026 is a big year for Denali with Hunter and the pipeline, and then we’ll do Q&A. So thanks again.

Ryan Watts
Co-Founder, President, CEO & Director

Sounds great, Paul. Great to be here again. I was trying to count how many CNS days this is for me, but probably…

Paul Matteis
Stifel Nicolaus Canada Inc., Research Division

6 or 7. Do you know the first one was not on video. Well, no, I’ve done 7. The first one for you was probably 6 years ago, audio-only 5 days into COVID.

Ryan Watts
Co-Founder, President, CEO & Director

Yes. I remember that.

Paul Matteis
Stifel Nicolaus Canada Inc., Research Division

Crazy. So thank you. Appreciate it.

Ryan Watts
Co-Founder, President, CEO & Director

It’s good to be back. And I think that might have even been a panel, if I recall, back…

Paul Matteis
Stifel Nicolaus Canada Inc., Research Division

Yes, that was interesting. We can talk about that another time. That was interesting.

Ryan Watts
Co-Founder, President, CEO & Director

I mean, 2026 is set up to be a very important year for Denali. I mean, obviously, we’re at the very final stages of our first approval for tividenofusp alfa in Hunter syndrome. I think not